CRA was commissioned by AstraZeneca to investigate the economic and societal burden associated with Acute Coronary Syndrome (ACS) in Canada. This short paper represents a summary of the full report.
Evidence requirements for orphan drugs
CRA’s Life Sciences Practice focuses on global policy, commercialization, and market access issues dedicated to orphan drug issues, including orphan evidence...